What it is
Human growth hormone is a protein made of 191 amino acids (the building blocks of proteins). 'HGH fragment 176-191' means the last 16 of them, made on their own in a laboratory. Read from the growth hormone sequence held by UniProt, that piece is FLRIVQCRSVEGSCGF. It contains two cysteines, which in the full hormone are joined to each other by a bridge (a disulfide bond); PubChem's record for the fragment shows the same bridge, which closes the short peptide into a loop.
More on what it is and where it came from
The name covers a mix-up between three close relatives. (1) The fat research at Monash University in Australia in the 1990s used hGH 177-191. It is one amino acid shorter (15 amino acids, starting LRIVQ) and was also coded AOD9401. (2) The drug candidate tested in people was AOD-9604. FDA describes it as hGH 177-191 with an extra tyrosine at the front, 16 amino acids in all; the developer's own paper says the tyrosine 'stabilizes the peptide'. (3) The true 176-191 fragment has phenylalanine at the front instead of tyrosine. AOD-9604 and the true 176-191 fragment are both 16 amino acids long and differ by a single oxygen atom (PubChem gives molecular weights of 1815.1 and 1799.1), so they are easy to confuse.
The names are used loosely even in journals. A 2022 cell study with 'Human Growth Hormone Fragment 176-191' in its title printed the AOD-9604 sequence (starting with tyrosine) in its methods. A 2026 review wrote 'AOD9604 (hGH 176-191)' as if they were one substance. WADA's Prohibited List and a 2026 anti-doping laboratory paper list them as two separate substances. A vial labelled 'HGH fragment 176-191' could hold either molecule, and only a lab test can tell. The evidence does not follow the label: the rodent fat studies used 177-191 or AOD-9604, and every human trial used AOD-9604. Almost nothing has been published on the exact 176-191 fragment.
F.M. Ng and J. Bornstein made short synthetic pieces of the tail end of human growth hormone in the 1970s. Their 1978 paper tested six of them, including hGH 176-191 and hGH 177-191, in normal rats and found that several briefly raised blood sugar. In 1993 and 1994, Ng's group in the Department of Biochemistry at Monash University reported that hGH 177-191 reduced fat-making in rat fat tissue and slowed weight gain in obese mice. The Australian company Metabolic Pharmaceuticals then developed AOD-9604 (177-191 with a tyrosine added) as an obesity drug and funded six human trials. On 21 February 2007 the company announced, as quoted by FDA, that the phase 2b results 'do not support the commercial viability of the drug as a treatment for obesity' and that development for that use was terminated. The unmodified 176-191 fragment was never taken into trials.
How it is thought to work
Nobody has identified the molecule in the body that these peptides act on. FDA wrote in 2024 that the molecular target and mechanism of AOD-9604 'remain unknown'. Nothing at all has been published on how the unmodified 176-191 fragment might work.
More on how it works
In rat fat tissue, hGH 177-191 appeared to slow the making of new fat (lipogenesis). A 1993 study found no significant effect on fat breakdown (lipolysis), while later studies of the same peptide (as AOD9401) reported more fat breakdown in rodent and human fat tissue in a dish. In obese mice, AOD-9604 appeared to increase fat burning and a blood marker of fat breakdown. In a cell test it did not attach to the growth hormone receptor and did not make the cells multiply, unlike full growth hormone.
The blood sugar picture is mixed. The 1978 work in normal rats found that peptides from this region, including 176-191, briefly raised blood sugar and reduced sensitivity to insulin. The later studies in obese rodents reported that AOD9401 and AOD-9604 did not cause insulin resistance. In mice bred without the beta-3 adrenergic receptor (a switch on fat cells), 14 days of AOD-9604 no longer reduced weight; the authors still concluded the effect is not directly through that receptor.
What is established in people
No study in people has used the unmodified hGH 176-191 fragment; searches of PubMed and ClinicalTrials.gov found none. All human data come from six company-funded trials of a different molecule, AOD-9604. The largest, a 24-week trial with 502 obese adults, did not show significant weight loss compared with placebo and was never published in a journal; the company ended obesity development in 2007. The published safety summary reported side effects at rates similar to placebo, but FDA judged the safety data too limited to draw conclusions.
What the studies found
11 studies, human trials first. Each links to the paper or registry record.
- Human trial2013
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Safety only; no weight results are given.
Full finding, who was studied, and limits
Who: DIFFERENT MOLECULE (AOD-9604). Company-written summary of six randomised, double-blind, placebo-controlled trials, 893 participants in all: two single-dose trials into a vein (15 healthy men; 23 obese men) and four by mouth (17 obese men, single doses; 36 obese men for 7 days; 300 obese adults for 12 weeks; 502 obese adults for 24 weeks at 16 Australian centres).
Safety only; no weight results are given. IGF-1 (a growth-related hormone) did not differ from placebo, glucose tolerance did not worsen, and no antibodies to the peptide were found in those tested. In the 24-week trial 78.7% of people on active treatment had at least one side effect, against 83.2% on placebo. The authors called the profile 'indistinguishable from placebo'.
Read with care: Funded by the developer; two authors worked for or consulted to it and the third worked for a firm consulting to it. One serious event (diarrhoea) in a single-dose oral trial was rated 'possibly related' to treatment, which conflicts with the paper's general statement. FDA said the summaries lacked detail. None of these trials used the unmodified 176-191 fragment.
- Review2024
FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate), Pharmacy Compounding Advisory Committee briefing document
FDA reported that in the 24-week 'OPTIONS' trial (502 randomised obese adults, with diet and exercise) there was no significant difference in weight loss between AOD-9604 and placebo, and quoted the company's 2007 statement that weight loss 'was too low to reach statistical significance' at 12 or 24 weeks.
Full finding, who was studied, and limits
Who: DIFFERENT MOLECULE (AOD-9604). FDA staff review of the chemistry, animal studies and human trials of AOD-9604.
FDA reported that in the 24-week 'OPTIONS' trial (502 randomised obese adults, with diet and exercise) there was no significant difference in weight loss between AOD-9604 and placebo, and quoted the company's 2007 statement that weight loss 'was too low to reach statistical significance' at 12 or 24 weeks. FDA found the trial was never published in a journal and that ClinicalTrials.gov listed no AOD-9604 studies. It concluded that 'in most of the studies reviewed' AOD-9604 failed to show weight benefit over placebo, noted serious events in a 12-week trial including several cancers that the investigators judged unrelated, and said the information was insufficient to judge whether they were related. FDA proposed not adding AOD-9604 to the compounding list.
Read with care: A regulatory review that relies on company summaries and press statements, not raw data. It does not discuss the unmodified 176-191 fragment.
- Animal study2001
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
Growth hormone and AOD-9604 both reduced weight gain in obese mice and raised fat burning and blood glycerol (a marker of fat breakdown).
Full finding, who was studied, and limits
Who: DIFFERENT MOLECULE (AOD-9604). Obese (ob/ob) and lean mice treated for 14 days with growth hormone, AOD-9604 or salt water, plus a test in cells carrying the human growth hormone receptor. Group sizes not given in the abstract.
Growth hormone and AOD-9604 both reduced weight gain in obese mice and raised fat burning and blood glycerol (a marker of fat breakdown). Growth hormone raised blood sugar and cut insulin release; AOD-9604 did neither. AOD-9604 did not attach to the growth hormone receptor or make the cells multiply. FDA's reading of the 2001 mouse studies is that treated obese mice gained about 5 to 10 percent less weight than untreated ones.
Read with care: Mice, 14 days, AOD-9604. FDA cautioned that none of these rodent studies tested how the effect changed with amount, and that the statistics were not corrected for multiple comparisons.
International Journal of Obesity and Related Metabolic Disorders · pubmed.ncbi.nlm.nih.gov
- Animal study2001
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
In obese mice, growth hormone and AOD-9604 both reduced body weight and body fat and restored beta-3 receptor gene activity to lean levels.
Full finding, who was studied, and limits
Who: DIFFERENT MOLECULE (AOD-9604). Obese mice and mice bred without the beta-3 adrenergic receptor, treated for 14 days, plus a single-treatment test. Group sizes not given in the abstract.
In obese mice, growth hormone and AOD-9604 both reduced body weight and body fat and restored beta-3 receptor gene activity to lean levels. In mice lacking the receptor, 14 days of treatment did not change weight or raise fat breakdown, although a single treatment still raised energy use and fat burning. The authors concluded the effect is not directly through the beta-3 receptor.
Read with care: Mice, AOD-9604. It points to a pathway but does not find the peptide's target.
- Animal study2000
Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats.
The peptide acted on fat tissue much like full growth hormone.
Full finding, who was studied, and limits
Who: Rat fat tissue in a dish, and obese Zucker rats treated for 20 days with AOD9401, which the abstract identifies as hGH residues 177-191.
The peptide acted on fat tissue much like full growth hormone. Over 20 days it reduced weight gain and fat-cell size in obese rats. Unlike growth hormone, it did not cause insulin resistance or poor glucose tolerance.
Read with care: Obese rats, 20 days, group sizes not in the abstract. The peptide is 177-191, not 176-191.
Journal of Molecular Endocrinology · pubmed.ncbi.nlm.nih.gov
- Animal study2000
Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.
From day 16 the treated mice gained significantly less weight than controls, while eating the same amount.
Full finding, who was studied, and limits
Who: Obese (ob/ob) mice given AOD-9401 by mouth for 30 days (10 treated, 8 on salt water), plus fat tissue from obese rodents and from people tested in a dish.
From day 16 the treated mice gained significantly less weight than controls, while eating the same amount. Their fat tissue made less new fat and broke down more. Energy use and fat and glucose burning rose shortly after treatment. Rodent and human fat tissue showed the same shift in a dish.
Read with care: Mice, small groups. The human part was tissue in a dish, not a trial. FDA's 2024 review set this paper aside because AOD-9401 is a different peptide from AOD-9604.
American Journal of Physiology. Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Animal study1994
Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide.
Treated obese mice gained less weight and had less fat tissue, and fat-making in their fat tissue was reduced.
Full finding, who was studied, and limits
Who: Genetically obese (ob/ob) mice given long-term hGH 177-191. Numbers and length of treatment not given in the abstract.
Treated obese mice gained less weight and had less fat tissue, and fat-making in their fat tissue was reduced. The authors suggested possible relevance to human obesity.
Read with care: Mice bred to be obese. No effect sizes in the abstract. The peptide is 177-191, not 176-191.
Biochemistry and Molecular Biology International · pubmed.ncbi.nlm.nih.gov
- Animal study1993
Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone.
hGH 177-191 reduced fat-making (lipogenesis) as much as full growth hormone did.
Full finding, who was studied, and limits
Who: Rats and rat fat tissue treated with synthetic hGH 177-191 (Monash University). Numbers not given in the abstract.
hGH 177-191 reduced fat-making (lipogenesis) as much as full growth hormone did. It had no significant effect on fat breakdown (lipolysis). The authors placed growth hormone's anti-fat-making action in this tail region.
Read with care: Rats and rat tissue; no numbers in the abstract. The peptide is 177-191, not the 176-191 fragment named on products.
Biochemistry and Molecular Biology International · pubmed.ncbi.nlm.nih.gov
- Animal study1978
Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.
This is the only animal study found that tests hGH 176-191 itself.
Full finding, who was studied, and limits
Who: Normal rats given six synthetic pieces of the tail end of growth hormone: hGH 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191. The abstract does not give the number of rats.
This is the only animal study found that tests hGH 176-191 itself. Pieces 172-191, 176-191, 177-191 and 178-191 each caused a short rise in blood sugar and a longer rise in blood insulin. The two shortest pieces did nothing. Peptides containing the 178-191 stretch significantly reduced the rats' sensitivity to insulin in an insulin tolerance test.
Read with care: Old study, normal rats, abstract only. It looked at blood sugar, not fat or weight. It cuts against the later claim that this part of growth hormone leaves blood sugar alone.
- Cell study2022
Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Particles carrying a chemotherapy drug plus the peptide reduced cancer-cell growth more than particles with the drug alone.
Full finding, who was studied, and limits
Who: Computer modelling plus one breast cancer cell line (MCF-7) in a dish. No animals or people.
Particles carrying a chemotherapy drug plus the peptide reduced cancer-cell growth more than particles with the drug alone. Although the title says 'fragment 176-191', the methods give the sequence YLRIVQCRSVEGSCGF, which is AOD-9604, not the true 176-191 fragment.
Read with care: Cells only; unrelated to fat loss. The paper does not say where the peptide came from or confirm its identity by lab test. It is included here because it shows the naming confusion in a journal.
Drug Design, Development and Therapy · pubmed.ncbi.nlm.nih.gov
- Cell study2000
The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone.
The abstract prints the 15-amino-acid sequence (Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) with a bridge between the two cysteines.
Full finding, who was studied, and limits
Who: Shape analysis of the looped 15-amino-acid peptide hGH 177-191, with tests on rodent, pig and human fat tissue in a dish.
The abstract prints the 15-amino-acid sequence (Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) with a bridge between the two cysteines. In a dish it increased fat breakdown and reduced fat-making in rodent, pig and human fat tissue. Its shape resembled the same region inside the full hormone.
Read with care: Laboratory structure and tissue work only.
Safety findings
- No human safety data exist for the unmodified hGH 176-191 fragment. Source: clinicaltrials.gov
- In normal rats, hGH 176-191 and related pieces briefly raised blood sugar and blood insulin, and peptides containing the 178-191 stretch reduced insulin sensitivity (1978 study). Source: pubmed.ncbi.nlm.nih.gov
- AOD-9604 (different molecule): in six company trials, side-effect rates were similar to placebo (78.7% on active treatment versus 83.2% on placebo in the 24-week trial). One serious case of diarrhoea was rated possibly related to treatment. Source: jofem.org
- AOD-9604 (different molecule): FDA noted serious events in a 12-week trial including basal cell carcinoma, squamous cell carcinoma, breast cancer and melanoma, which investigators judged unrelated; FDA said there was not enough information to judge. It also listed chest tightness and euphoria as side effects reported as possibly related after injection into a vein, and said 16-amino-acid peptides can provoke immune reactions. Source: fda.gov
1 more safety findings
- FDA's compounding safety page says compounded AOD-9604 'may pose significant risk for immunogenicity' (immune reactions) and that serious adverse events may be associated with it, 'though causality is not clear'. Source: fda.gov
Rules and status
Not approved by FDA for any use. HGH fragment 176-191 does not appear on FDA's list of substances nominated for pharmacy compounding (any category) or on FDA's compounding safety-risks page. Its close relative AOD-9604 is on that page as 'nominated but withdrawn', and an FDA advisory committee voted 12 to 0 against adding AOD-9604 to the compounding list.
The full history, with dates
Approval: no FDA approval was found for hGH 176-191 or for AOD-9604. Compounding lists: the name 'hGH 176-191' (or any growth hormone fragment) does not appear in Category 1, 2 or 3 of FDA's '503A' list of bulk substances nominated for compounding, updated 14 May 2026, nor on FDA's page 'Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks', content current as of 22 April 2026. That page lists AOD-9604 (a different molecule) in its 'nominated but withdrawn' table, with FDA's stated reason: 'Compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.' FDA evaluated AOD-9604 anyway; at the Pharmacy Compounding Advisory Committee meeting of 4 December 2024 the committee voted Yes 0, No 12, Abstain 0 on placing AOD-9604 (free base and acetate) on the 503A list (FDA final summary minutes). 2026 HHS notice: on 30 October 2026 HHS published a Federal Register notice (91 FR 68526) of a draft, non-binding enforcement-discretion policy for 503A compounding of certain peptides. Appendix A of that policy names six peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500); neither hGH 176-191 nor AOD-9604 is among them. The policy is a draft and interim, not a rule. Products sold online 'for research' are not covered by any of these compounding pathways.
Source: fda.gov (source dated 2026-05-14)
In sport: Prohibited at all times (in and out of competition). The 2026 List, and the 2027 List published 21 September 2026, both read under S2.2.3 'Growth hormone (GH), its analogues and fragments including, but not limited to': 'growth hormone fragments, e.g. AOD-9604 and hGH 176-191'. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| HGH fragment 176-191 is proven to burn fat. | The unmodified fragment has no published fat-loss studies at all. The fat studies used hGH 177-191 or AOD-9604 in obese rodents and fat tissue in a dish. In people, the largest AOD-9604 trial did not show significant weight loss versus placebo. Source: fda.gov |
| HGH fragment 176-191 and AOD-9604 are the same thing. | They are different molecules. AOD-9604 starts with tyrosine; the true 176-191 fragment starts with phenylalanine. PubChem gives them separate records with different formulas and weights, and WADA names them separately. Source: pubchem.ncbi.nlm.nih.gov |
| It has the fat-burning effect of growth hormone without affecting blood sugar. | In obese rodents, AOD9401 and AOD-9604 did not cause insulin resistance. But the only animal study of hGH 176-191 itself (1978) found it briefly raised blood sugar in normal rats, and related peptides reduced insulin sensitivity. Source: pubmed.ncbi.nlm.nih.gov |
| It has been shown to be safe in human trials. | No human trial has used the 176-191 fragment. The AOD-9604 trials were company-funded and only summarised; FDA said the data were too limited to judge safety, including cancers reported in one 12-week trial. Source: fda.gov |
| It is legal for pharmacies to compound. | It is not on FDA's compounding category list, and HHS's October 2026 draft policy covers six other peptides, not this one. FDA's advisory committee voted 12 to 0 against adding AOD-9604. Source: fda.gov |
What a genuine lab report should show
- Identity by mass spectrometry matching the molecule named on the label. The true hGH 176-191 fragment has a molecular weight of 1799.1 g/mol (free peptide, PubChem); AOD-9604 is 1815.1 g/mol. A difference of about 16 is the main way to tell them apart, so a report that only says 'HGH Frag 176-191' without the measured mass does not show which molecule is in the vial.
- The sequence or amino-acid analysis should start with phenylalanine (F), not tyrosine (Y): FLRIVQCRSVEGSCGF.
- Purity by HPLC (high-performance liquid chromatography), with the main peak identified and impurities listed.
- Evidence that the two cysteines are joined (the disulfide bridge), since the open-chain form weighs slightly more.
- Whether the product is a salt (for example acetate or trifluoroacetate) and how much of the powder is peptide (net peptide content).
- A 2026 anti-doping laboratory study found that hGH 176-191 and AOD-9604 broke down substantially in liquid serum and plasma within a week at fridge and room temperature, which is a reminder that the peptide is fragile.
What is not known
- Whether anything has been published on the unmodified 176-191 fragment beyond the 1978 rat blood sugar study and the mislabelled 2022 cell study. PubMed and ClinicalTrials.gov searches found nothing else, but older non-indexed literature may exist.
- What products sold as 'HGH fragment 176-191' actually contain. Because papers and sellers mix the names, some may be AOD-9604 or hGH 177-191.
- The full results of the 24-week AOD-9604 trial were never published in a journal; only company statements and FDA's summary of them are available.
- Whether the cancers reported in the 12-week AOD-9604 trial were related to the drug. FDA said the information was insufficient to decide.
- Small inconsistencies in primary sources: FDA's 2024 briefing places AOD-9604's extra tyrosine at the front in one section and the 'C-terminal' end in another, and gives 21 days for a rat study whose abstract says 19 days.
- The current text of the federal regulation listing approved 503A bulk substances (21 CFR 216.23) could not be opened; the conclusion that the fragment is not on any FDA compounding list rests on FDA's May 2026 category list and April 2026 safety page.
Sources
All 27 sources
- PubChem: Somatotropin (176-191), CID 16131230. pubchem.ncbi.nlm.nih.gov
- PubChem: HGH Fragment 176-191 (with acetic acid), CID 172966176. pubchem.ncbi.nlm.nih.gov
- PubChem: AOD-9604, CID 71300630. pubchem.ncbi.nlm.nih.gov
- UniProt P01241, human growth hormone (sequence, signal peptide 1-26, chain 27-217, disulfide 208-215). uniprot.org
- Ng and Bornstein 1978, Am J Physiol (hGH 176-191 in rats). pubmed.ncbi.nlm.nih.gov
- Wu and Ng 1993, hGH 177-191 antilipogenic action. pubmed.ncbi.nlm.nih.gov
- 1993, hGH 177-191 and glucose transport in rat fat cells. pubmed.ncbi.nlm.nih.gov
- Natera, Jiang and Ng 1994, hGH 177-191 in obese mice. pubmed.ncbi.nlm.nih.gov
- Ng et al. 2000, AOD9401 (hGH 177-191) in Zucker rats. pubmed.ncbi.nlm.nih.gov
- Heffernan et al. 2000, oral AOD-9401 in obese mice. pubmed.ncbi.nlm.nih.gov
- Ogru et al. 2000, structure of cyclic hGH 177-191. pubmed.ncbi.nlm.nih.gov
- Ng et al. 2000, Horm Res, oral AOD9604 in obese Zucker rats. pubmed.ncbi.nlm.nih.gov
- Heffernan et al. 2001, Int J Obes, AOD-9604 in obese mice. pubmed.ncbi.nlm.nih.gov
- Heffernan et al. 2001, Endocrinology, AOD9604 and beta-3 receptor knockout mice. pubmed.ncbi.nlm.nih.gov
- Stier, Vos and Kenley 2013, safety of AOD9604 in six human trials. jofem.org
- FDA PCAC briefing document on AOD-9604, November 2024. fda.gov
- FDA PCAC final summary minutes, 4 December 2024 (AOD-9604 vote 0-12). fda.gov
- Habibullah et al. 2022, 'hGH fragment 176-191' cell study (AOD-9604 sequence). pubmed.ncbi.nlm.nih.gov
- Dominikowski et al. 2026 review, 'AOD9604 (hGH 176-191)'. pubmed.ncbi.nlm.nih.gov
- Mazzarino et al. 2026, anti-doping blood test method listing hGH 176-191 and AOD9604 separately. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov search for '176-191' (no studies). clinicaltrials.gov
- FDA: bulk drug substances that may present significant safety risks (current as of 22 April 2026). fda.gov
- FDA: 503A nominated bulk drug substances by category (updated 14 May 2026). fda.gov
- HHS 503A peptide enforcement-discretion policy, Appendix A and B (Internet Archive capture, 15 November 2026). hhs.gov
- Federal Register, 30 October 2026, 91 FR 68526. govinfo.gov
- WADA 2026 Prohibited List. wada-ama.org
- WADA 2027 Prohibited List. wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.